[go: up one dir, main page]

PE20180398A1 - Unidad de dosificacion orodispersable que contiene un componente estetrol - Google Patents

Unidad de dosificacion orodispersable que contiene un componente estetrol

Info

Publication number
PE20180398A1
PE20180398A1 PE2017002731A PE2017002731A PE20180398A1 PE 20180398 A1 PE20180398 A1 PE 20180398A1 PE 2017002731 A PE2017002731 A PE 2017002731A PE 2017002731 A PE2017002731 A PE 2017002731A PE 20180398 A1 PE20180398 A1 PE 20180398A1
Authority
PE
Peru
Prior art keywords
estetrol
dosage unit
weight
component
solid
Prior art date
Application number
PE2017002731A
Other languages
English (en)
Inventor
Severine Francine Isabelle Jaspart
Johannes Jan Platteeuw
Den Heuvel Denny Johan Marijn Van
Original Assignee
Mithra Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mithra Pharmaceuticals S A filed Critical Mithra Pharmaceuticals S A
Publication of PE20180398A1 publication Critical patent/PE20180398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona una unidad de dosificacion solida orodispersable farmaceutica que tiene un peso comprendido entre 30 y 1.000 mg, consistiendo dicha unidad de dosificacion en: 0,1-25 % en peso de particulas de estetrol que contienen al menos 80 % en peso de un componente estetrol seleccionado entre estetrol, esteres de estetrol y combinaciones de los mismos; y 75-99,9 % en peso de uno o mas ingredientes farmaceuticamente aceptables; comprendiendo la unidad de dosificacion solida al menos 100 microgramo del componente estetrol; y en la que la unidad de dosificacion solida se puede obtener mediante un procedimiento que comprende la compresion de una mezcla seca de particulas de estetrol y uno o mas excipientes farmaceuticamente aceptables en una unidad de dosificacion solida. La unidad de dosificacion solida es facil de fabricar y perfectamente adecuada para su administracion sublingual, bucal o sublabial.
PE2017002731A 2015-06-18 2016-06-17 Unidad de dosificacion orodispersable que contiene un componente estetrol PE20180398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15172747 2015-06-18

Publications (1)

Publication Number Publication Date
PE20180398A1 true PE20180398A1 (es) 2018-02-28

Family

ID=53442623

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002731A PE20180398A1 (es) 2015-06-18 2016-06-17 Unidad de dosificacion orodispersable que contiene un componente estetrol

Country Status (43)

Country Link
US (3) US20160367567A1 (es)
EP (1) EP3106148B1 (es)
JP (1) JP6863547B2 (es)
KR (1) KR102664563B1 (es)
CN (2) CN107771075A (es)
AU (1) AU2016280863B2 (es)
CA (1) CA2988498C (es)
CL (1) CL2017003208A1 (es)
CO (1) CO2017012766A2 (es)
CR (1) CR20180042A (es)
CU (1) CU24523B1 (es)
CY (1) CY1120467T1 (es)
DK (1) DK3106148T3 (es)
DO (1) DOP2017000293A (es)
EA (1) EA035651B1 (es)
EC (1) ECSP17085669A (es)
ES (1) ES2671160T3 (es)
GE (1) GEP20217308B (es)
GT (1) GT201700270A (es)
HK (1) HK1251940A1 (es)
HR (1) HRP20180889T1 (es)
HU (1) HUE037383T2 (es)
IL (1) IL256283B (es)
LT (1) LT3106148T (es)
MX (1) MX385820B (es)
MY (1) MY195019A (es)
NO (1) NO3106148T3 (es)
NZ (1) NZ737948A (es)
PE (1) PE20180398A1 (es)
PH (1) PH12017502325B1 (es)
PL (1) PL3106148T3 (es)
PT (1) PT3106148T (es)
RS (1) RS57328B1 (es)
SA (1) SA517390550B1 (es)
SG (1) SG10202010432UA (es)
SI (1) SI3106148T1 (es)
SM (1) SMT201800232T1 (es)
SV (1) SV2017005595A (es)
TN (1) TN2017000499A1 (es)
TR (1) TR201808438T4 (es)
UA (1) UA123098C2 (es)
WO (1) WO2016203011A1 (es)
ZA (1) ZA201708287B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2714712T3 (pl) 2011-06-01 2017-05-31 Estetra S.P.R.L. Metoda wytwarzania półproduktów estetrolu
CN107266514A (zh) 2011-06-01 2017-10-20 埃斯特拉私人有限责任公司 用于产生雌四醇中间体的方法
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CA2988485A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
PE20180522A1 (es) 2015-06-18 2018-03-14 Mithra Pharmaceuticals S A Unidad de dosificacion orodispersable que contiene un componente estetrol
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
EP3310346B1 (en) 2015-06-18 2021-03-24 Estetra SPRL Orodispersible tablet containing estetrol
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
AU2021351921A1 (en) 2020-09-29 2023-04-06 Millicent Pharma Limited Orodispersible formulations

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
CA1306950C (en) 1987-04-10 1992-09-01 Alec D. Keith Buccal administration of estrogens
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
GB2228412B (en) 1989-02-28 1993-04-14 Syntex Inc Nicardipine pharmaceutical composition for parenteral administration
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
BR9813808A (pt) 1997-12-19 2002-05-28 Smithkline Beecham Corp Processo para produção de comprimidos para dispersão na mordida
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
IL149424A (en) 1999-12-02 2007-05-15 Organon Nv Androgens are converted to methylene at positions 15,14
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
DE60101276T2 (de) * 2001-05-23 2004-04-22 Pantarhei Bioscience B.V. Zubereitungen für die hormonale Kontrazeption
PT1390042E (pt) 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
ES2337129T3 (es) 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ATE347365T1 (de) * 2001-11-15 2006-12-15 Pantarhei Bioscience Bv Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
KR100936827B1 (ko) 2002-02-21 2010-01-14 바이엘 쉐링 파마 악티엔게젤샤프트 하나 이상의 스테로이드, 하나 이상의테트라히드로폴레이트 성분 및 비타민 ｂ12를 포함하는제약 조성물
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CN1691947B (zh) 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物
CA2489270C (en) 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
CN100374116C (zh) 2002-07-12 2008-03-12 潘塔希生物科学股份有限公司 用于癌症治疗的含有雌四醇衍生物的药物组合物
BR0313921A (pt) 2002-08-28 2005-07-19 Gideon Kopernik Regime de reposição de estrogênio
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
DE60330888D1 (de) 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
DE60332754D1 (de) 2002-11-08 2010-07-08 Pantarhei Bioscience Bv Synthese von oestetrol aus von oestron abgeleiteten steroiden
ATE340580T1 (de) 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
WO2005030175A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Hrt formulations
EP2409690B1 (en) 2003-09-29 2022-11-09 Novo Nordisk Health Care AG Improved stability of progestogen formulations
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DK1755562T3 (da) 2004-05-28 2013-12-16 Richter Gedeon Nyrt Kontraceptivum, som indeholder folsyre
ATE424814T1 (de) 2004-07-01 2009-03-15 Lek Pharmaceuticals Schnell zerfallende im mund dispergierbare zusammensetzung mit nicht-filamentösen mitverarbeiteten polyol-teilchen und verkieselter mikrokristalliner cellulose
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
UA88943C2 (ru) 2005-02-03 2009-12-10 Нікомед Фарма Ас Быстрый способ влажного гранулирования для получения композиций, которые содержат кальций
IS7724A (is) 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
KR101364412B1 (ko) 2005-05-26 2014-02-21 애보트 프러덕츠 게엠베하 17β-ＨＳＤ1 및 ＳＴＳ 억제제들
US20070048369A1 (en) * 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
ES2352547T3 (es) * 2006-01-09 2011-02-21 Pantarhei Bioscience B.V. Método para tratar un trastorno vascular agudo.
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
WO2007106264A2 (en) 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
EP2029146B8 (en) 2006-06-08 2018-02-21 Allergan Pharmaceuticals International Limited Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CA2665788A1 (en) 2006-07-06 2008-01-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
CA2670544A1 (en) 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
WO2008079245A2 (en) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
CA2674325A1 (en) 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
MX2009007254A (es) 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
ATE537833T1 (de) 2007-06-21 2012-01-15 Pantarhei Bioscience Bv Behandlung des mekoniumaspirationssyndroms mit östrogenen
CN101778635A (zh) 2007-07-19 2010-07-14 潘塔希生物科学股份有限公司 妊娠高血压病变或胎儿生长迟缓的治疗或预防
FR2920311B1 (fr) 2007-08-31 2010-06-18 Galenix Innovations Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation
JP5399749B2 (ja) 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
CN101780073B (zh) 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
EP2210591B1 (en) 2009-01-26 2016-03-30 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP2410995A1 (en) 2009-03-26 2012-02-01 Royal College of Surgeons in Ireland Orodispersible tablets
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
PE20120860A1 (es) 2009-06-23 2012-07-15 Bayer Ip Gmbh Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
EP2646003B1 (en) 2010-12-02 2020-06-03 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
CN107266514A (zh) 2011-06-01 2017-10-20 埃斯特拉私人有限责任公司 用于产生雌四醇中间体的方法
PL2714712T3 (pl) 2011-06-01 2017-05-31 Estetra S.P.R.L. Metoda wytwarzania półproduktów estetrolu
HUE025350T2 (en) 2011-07-19 2016-02-29 Pantarhei Bioscience Bv Tablets containing dehydroepiandrosterone (DHEA)
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
SI2741824T1 (sl) 2011-08-11 2017-06-30 Estetra S.P.R.L. Uporaba estetrola kot urgentnega kontracepcijskega sredstva
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
KR102007874B1 (ko) 2011-10-07 2019-08-06 에스테트라 에스.피.알.엘. 에스테트롤 제조 방법
WO2013090117A1 (en) 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9238265B2 (en) 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
WO2014189836A1 (en) 2013-05-21 2014-11-27 Bradley Robinson Therapeutic and method of use
CA2924255C (en) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Process for the preparation of estetrol
US12274276B2 (en) 2013-10-03 2025-04-15 Altria Client Services Llc Dissolvable-chewable tablet
JP6447931B2 (ja) 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． エステトロール成分を含有する口腔内崩壊固体単位剤形
EP3200802B1 (en) 2014-09-29 2023-07-12 The Regents of The University of California Compositions and methods for maintaining cognitive function
CA2986039A1 (en) 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
PE20180522A1 (es) 2015-06-18 2018-03-14 Mithra Pharmaceuticals S A Unidad de dosificacion orodispersable que contiene un componente estetrol
CA2988485A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
EP3310346B1 (en) 2015-06-18 2021-03-24 Estetra SPRL Orodispersible tablet containing estetrol
CN108025014B (zh) 2015-06-23 2021-10-22 莱昂实验室制药股份有限公司 用于过重女性患者的基于屈螺酮的避孕药
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
UA126746C2 (uk) 2018-02-07 2023-01-18 Естетра Спрл Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
AU2016280863A1 (en) 2018-01-18
PH12017502325B1 (en) 2021-04-14
SMT201800232T1 (it) 2018-07-17
JP2018517717A (ja) 2018-07-05
CY1120467T1 (el) 2019-07-10
MX2017016276A (es) 2018-06-19
SI3106148T1 (en) 2018-08-31
MX385820B (es) 2025-03-18
GEP20217308B (en) 2021-10-25
EP3106148B1 (en) 2018-03-14
CN107771075A (zh) 2018-03-06
UA123098C2 (uk) 2021-02-17
TN2017000499A1 (en) 2019-04-12
CU24523B1 (es) 2021-06-08
MY195019A (en) 2023-01-03
TR201808438T4 (tr) 2018-07-23
CU20170159A7 (es) 2018-07-05
SV2017005595A (es) 2018-09-10
IL256283A (en) 2018-02-28
ZA201708287B (en) 2020-01-29
CN116077454A (zh) 2023-05-09
EP3106148A1 (en) 2016-12-21
NZ737948A (en) 2023-03-31
DK3106148T3 (en) 2018-05-07
US10660903B2 (en) 2020-05-26
JP6863547B2 (ja) 2021-04-21
DOP2017000293A (es) 2018-01-31
CA2988498A1 (en) 2016-12-22
LT3106148T (lt) 2018-06-25
US20190125759A1 (en) 2019-05-02
KR20180021085A (ko) 2018-02-28
US20200352959A1 (en) 2020-11-12
CL2017003208A1 (es) 2018-04-13
KR102664563B1 (ko) 2024-05-09
PL3106148T3 (pl) 2018-08-31
EA201890084A1 (ru) 2018-05-31
CO2017012766A2 (es) 2018-03-28
ES2671160T3 (es) 2018-06-05
CR20180042A (es) 2018-05-03
AU2016280863B2 (en) 2021-04-01
NO3106148T3 (es) 2018-08-11
HK1251940A1 (zh) 2019-05-03
WO2016203011A1 (en) 2016-12-22
EA035651B1 (ru) 2020-07-22
SA517390550B1 (ar) 2022-03-16
PH12017502325A1 (en) 2018-06-25
US20160367567A1 (en) 2016-12-22
SG10202010432UA (en) 2020-11-27
PT3106148T (pt) 2018-05-10
ECSP17085669A (es) 2018-03-31
GT201700270A (es) 2019-08-30
HUE037383T2 (hu) 2018-08-28
IL256283B (en) 2021-02-28
HRP20180889T1 (hr) 2018-08-10
CA2988498C (en) 2022-02-08
RS57328B1 (sr) 2018-08-31
US11957694B2 (en) 2024-04-16

Similar Documents

Publication Publication Date Title
PE20180398A1 (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
PE20231714A1 (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
MX394356B (es) Métodos y composiciones para tratar hiperhidrosis.
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
CL2024000431A1 (es) Contra enfermedades inflamatorias intestinales que involucra la disrupción del ensamblaje de heterómeros ccr9:drd5
DOP2022000004A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
CR20190401A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
MX380487B (es) Fructanos de agave como excipiente farmacéutico funcional en una forma de dosificación de liberación inmediata.